INmune Bio (NASDAQ:INMB) Posts Quarterly Earnings Results, Beats Estimates By $0.16 EPS

INmune Bio (NASDAQ:INMB) issued its earnings results on Thursday. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.16, Zacks reports.

Here are the key takeaways from INmune Bio’s conference call:

• Positive Sentiment: INmune Bio expects to submit Ebstrocel’s U.K. marketing authorization application by the end of Q3 or early Q4 2026, followed by EMA and U.S. submissions in early 2027. MHRA alignment across clinical, non-clinical, and CMC requirements, plus approval of the pediatric investigation plan, reduces regulatory uncertainty.
• Positive Sentiment: Ebstrocel manufacturing and supply-chain readiness advanced, including commercial-ready cord-tissue processing, transfer of MSC isolation to the intended commercial facility, and expanded access to umbilical cord tissue through Anthony Nolan. Management believes this supports scalable supply for potential U.K., European, and U.S. commercialization.
• Positive Sentiment: XPro received FDA Fast Track designation for early Alzheimer’s disease, while the MINDFuL Phase II study showed statistically significant improvement in white-matter myelin MRI biomarkers. Management is advancing a registrational strategy and evaluating partnerships, although Alzheimer’s remains the clinical priority.
• Neutral Sentiment: The company reported $18.4 million in cash at June 30 and received a subsequent $4.2 million Australian R&D rebate, with funding expected to last into Q2 2027. Management estimates a forward burn rate of roughly $1 million to $1.5 million per month and expects to raise capital selectively, but future financing could still create dilution.
• Positive Sentiment: If approved, management estimates a U.K. opportunity of roughly 800 RDEB patients and anticipates pricing of approximately £400,000–£500,000 per child annually, subject to reimbursement negotiations. The company also highlighted a potential U.S. rare pediatric disease priority review voucher, which it estimates could be worth $100 million to $200 million, though neither approval nor monetization is assured.

INmune Bio Stock Performance

Shares of INMB stock traded up $0.16 during trading hours on Friday, hitting $2.07. 558,777 shares of the company were exchanged, compared to its average volume of 546,597. The stock has a market capitalization of $55.10 million, a price-to-earnings ratio of -1.24 and a beta of 0.97. INmune Bio has a one year low of $1.09 and a one year high of $2.61. The business’s 50-day simple moving average is $1.61 and its two-hundred day simple moving average is $1.47.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on INMB shares. Wall Street Zen downgraded shares of INmune Bio from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. Weiss Ratings downgraded INmune Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy”.

Institutional Trading of INmune Bio

Several institutional investors and hedge funds have recently bought and sold shares of INMB. Jain Global LLC bought a new stake in shares of INmune Bio in the 4th quarter valued at approximately $66,000. Charles Schwab Investment Management Inc. lifted its stake in INmune Bio by 20.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 50,252 shares of the company’s stock worth $78,000 after purchasing an additional 8,427 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in INmune Bio by 269.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 56,477 shares of the company’s stock worth $88,000 after purchasing an additional 41,173 shares during the last quarter. Oxford Asset Management LLP acquired a new position in INmune Bio in the second quarter worth $52,000. Finally, JPMorgan Chase & Co. increased its stake in INmune Bio by 1,042.7% during the second quarter. JPMorgan Chase & Co. now owns 73,097 shares of the company’s stock valued at $169,000 after purchasing an additional 66,700 shares during the last quarter. Institutional investors and hedge funds own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.